Abiopharma

🔍 Hite Christopher (Executive)

Company: Royalty Pharma plc (RPRX)

Report Date: 2026-08-18

Detailed Transactions and Holdings:

• Sold 100,000 shares of Class A Ordinary Shares at $59.9725 per share (Direct)
  Date: 2026-08-18 | Code: S | equity_swap_involved: 0 | shares_owned_after: 370,401.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Sold 16,800 shares of Class A Ordinary Shares (Direct)
  Date: 2026-08-19 | Code: G | equity_swap_involved: 0 | shares_owned_after: 23,200.00 | transaction_form_type: 4 | Footnotes: F3

Footnotes:

• F1: All reported sales were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on March 20, 2026.
• F2: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $59.68 to $60.42 per share. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
• F3: The Reporting Person made a charitable gift of Class A Ordinary Shares to Lehigh University.
• REMARKS: In addition to the Class A Ordinary Shares disclosed above, family vehicles controlled by the Reporting Person hold limited partnership interests in RPI US Partners 2019, LP exchangeable into 866,410 Class A Ordinary Shares and Class E Ordinary Shares of Royalty Pharma Holdings Ltd ("RPH") exchangeable into 1,238,789 Class A Ordinary Shares. Class E Ordinary Shares of RPH are subject to vesting conditions.